Different hair loss patterns in two pediatric patients with COVID‐19‐associated multisystem inflammatory syndrome in children

Hayran, Yıldız; Yorulmaz, Ahu; Gür, Güneş; Aktaş, Akın

doi:10.1111/dth.14820

Cited by 18 publications

(20 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 2 delineates the demographics and clinical characteristics of patients with hair loss and COVID‐19 ( n = 58), with a predominance of female patients (17.2% male and 82.8% female). 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 Hair loss type was predominately TE (74.1%), with the next most common hair loss type being early‐onset effluvium (12.1%). Only a small number of individuals had other types of hair loss including AA (5.2%), fibrosing alopecia (3.4%), and one individual each with alopecia areata totalis (1.7%), alopecia areata universalis (1.7%), and anagen effluvium (1.7%).…”

Section: Resultsmentioning

confidence: 99%

Characteristics of hair loss after COVID‐19: A systematic scoping review

Czech

Sugihara

Nishimura

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Objective While there are literature reporting increased incidence of hair loss in COVID‐19 patients, insufficient evidence exists on the topic to date. This review aims to identify the existing evidence and clinical characteristics of hair loss with COVID‐19 infection. Methods Following the PRISMA Extension for Scoping Reviews, MEDLINE and EMBASE were searched for all peer‐reviewed articles with relevant keywords including “Alopecia,” “Telogen Effluvium (TE),” and “COVID‐19” from their inception to November 20, 2021. Results A total of 26 articles, with 9 observational studies and 17 case reports or series (a total of 58 cases), were included. Most studies dealt with TE. There were no clear trends between COVID‐19 severity and the extent of hair loss. Analysis of the 58 cases also found similar results with most of the cases being female (82.8%), the median onset of hair loss of 2.0 months, and the median time to recovery of hair loss of 5.0 months with a resolution rate of 95%. Conclusion While this systematic review revealed uncertainty and a lack of strong evidence regarding the association of COVID‐19 and hair loss, hair loss in COVID‐19 may mainly include TE and be reversible in nature. Future studies are warranted to determine the detailed pathophysiology and risk factors of hair loss in COVID‐19, including possible roles of estrogen, progesterone, and pro‐inflammatory cytokines.

show abstract

Section: Resultsmentioning

confidence: 99%

Characteristics of hair loss after COVID‐19: A systematic scoping review

Czech

Sugihara

Nishimura

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…Hair loss following the infection by SARS‐CoV‐2 did not spare the pediatric population: As a matter of fact, Hayran at al 17 . described two patients who were 10 and 13 years of age who developed TE and alopecia areata, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Hair loss following the infection by SARS-CoV-2 did not spare the pediatric population: As a matter of fact, Hayran at al. 17 A recently published multicentric Spanish study identified 191 cases of post-infectious TE related to COVID-19: 78.5% of the patients were female, and 21.4% were male 20 . The mean age of the cohort was 47,4 years (range 15-88), and the days between coronavirus detection and beginning of hair loss were 57,1 (SD 18,3) on average 20 .…”

Section: Re Sultsmentioning

confidence: 99%

Hair and nail manifestations of COVID‐19

Tammaro

Adebanjo

Parisella

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Emerging literature evidence shows that the manifestations of the coronavirus disease 2019 (COVID‐19), which is the disease caused by SARS‐CoV‐2, encompass alterations of the pulmonary, cardiovascular, gastrointestinal, and neurological system. Moreover, hematologic and dermatologic manifestations have been documented. The aim of this review is to summarize the dermatologic manifestations of COVID‐19 involving the hair and nails in a narrative way. A total of 1136 patients have been reported to have de novo hair loss following COVID‐19. Notably, 958 patients experienced telogen effluvium (TE) (female/male ratio = 3,86:1), two female patients experienced anagen effluvium, and 176 people had alopecia areata (female/male ratio of 19:3). Ten patients were reported to have ungual changes following the infection with the novel coronavirus: The individuals affected were 6 women and 4 men. COVID‐19 can be associated with hair and ungual manifestations. This review summarizes the evidence regarding the hair and ungual manifestations of COVID‐19, which could be harnessed to better understand the clinical implications and pathophysiology of this disease that has been burdening society globally since December 2019.

show abstract

“…Individual patient characteristics for reports of new-onset alopecia areata following SARS-CoV-2 infection are outlined in Table I. [6][7][8][9][10][11] The average age of the patients was 37 years (range, 13-56 years). Four patients (57%) were female, and 3 patients (43%) were male.…”

Section: Resultsmentioning

confidence: 99%

Association between alopecia areata and COVID-19: A systematic review

Christensen

Jafferany

2022

JAAD International

View full text Add to dashboard Cite

Background COVID-19 may play a role in various immune-related dermatological conditions. The relationship between COVID-19 and alopecia areata remains unclear. Objective To review the existing literature for clinical studies and reports investigating the association between new-onset alopecia areata or the exacerbation of pre-existing alopecia areata following infection with SARS-CoV-2. Methods A systematic review of the literature was performed using PubMed, Embase, and MEDLINE databases from inception to October 2021. Included articles assessed alopecia areata following infection with SARS-CoV-2. Results Of 402 total articles, nine were identified as meeting inclusion criteria. Six articles described case reports of seven patients with new-onset alopecia areata following confirmed infection with SARS-CoV-2, and three articles reported on alopecia areata recurrence or exacerbation following SARS-CoV-2 infection in patients with pre-existing disease. Studies investigating the exacerbation or recurrence of alopecia areata following infection report mixed findings. Limitations A majority of included studies were case reports. Heterogeneity of articles precluded data synthesis. Conclusions Alopecia areata may be a dermatological manifestation of COVID-19, with cases most often appearing 1-2 months following infection. Additional research is necessary to better elucidate the relationship and draw conclusions.

show abstract

Different hair loss patterns in two pediatric patients with COVID‐19‐associated multisystem inflammatory syndrome in children

Abstract: Interpretation of the data; critical review of the literature; critical review of the manuscript. Akın Aktaş: Interpretation of the data; critical review of the literature; critical review of the manuscript.

Cited by 18 publications

References 4 publications

Characteristics of hair loss after COVID‐19: A systematic scoping review

Characteristics of hair loss after COVID‐19: A systematic scoping review

Hair and nail manifestations of COVID‐19

Association between alopecia areata and COVID-19: A systematic review

Contact Info

Product

Resources

About